guest ::
| Home > Articles > Published articles > Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients : |
| Home > Articles > Published articles > Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients : |
(Hospital Universitari Vall d'Hebron) (Hospital Universitari Vall d'Hebron) (Centro de Investigación Biomédica en Red de Cáncer) (Hospital Universitari Vall d'Hebron. Institut de Recerca) (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut)| Date: | 2021 |
| Abstract: | In this manuscript, we review the management strategies available for high-grade serous ovarian cancer patients and the molecular advances that are helping improve our understanding of the tumor and its response to treatment. We emphasize the role that proteomics is now playing in the study of ovarian cancer tumors and how its integration with genomics can guide the development of new biomarkers and therapeutic targets. High-grade serous ovarian cancer (HGSC) remains the most common and deadly subtype of ovarian cancer. It is characterized by its late diagnosis and frequent relapse despite standardized treatment with cytoreductive surgery and platinum-based chemotherapy. The past decade has seen significant advances in the clinical management and molecular understanding of HGSC following the publication of the Cancer Genome Atlas (TCGA) researchers and the introduction of targeted therapies with anti-angiogenic drugs and poly(ADP-ribose) polymerase inhibitors in specific subgroups of patients. We provide a comprehensive review of HGSC, focusing on the most important molecular advances aimed at providing a better understanding of the disease and its response to treatment. We emphasize the role that proteomic technologies are now playing in these two aspects of the disease, through the identification of proteins and their post-translational modifications in ovarian cancer tumors. Finally, we highlight how the integration of proteomics with genomics, exemplified by the work performed by the Clinical Proteomic Tumor Analysis Consortium (CPTAC), can guide the development of new biomarkers and therapeutic targets. |
| Grants: | Instituto de Salud Carlos III PT17/0019 Ministerio de Economía y Competitividad CTQ2016-80364-P Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR595 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR1661 Instituto de Salud Carlos III PI15/02238 Instituto de Salud Carlos III PI18/01017 Instituto de Salud Carlos III CPII18/00027 Ministerio de Economía y Competitividad RTC-2015-3821 |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Subject: | Ovarian cancer ; Mass spectrometry ; Proteomics ; Genomics ; Cancer tissue ; Biomarker |
| Published in: | Cancers, Vol. 13 (april 2021) , ISSN 2072-6694 |
